Literature DB >> 17500482

In vitro study of cell survival following dynamic MLC intensity-modulated radiation therapy dose delivery.

Vitali Moiseenko1, Cheryl Duzenli, Ralph E Durand.   

Abstract

The possibility of reduced cell kill following intensity-modulated radiation therapy (IMRT) compared to conventional radiation therapy has been debated in the literature. This potential reduction in cell kill relates to prolonged treatment times typical of IMRT dose delivery and consequently increased repair of sublethal lesions. While there is some theoretical support to this reduction in cell kill published in the literature, direct experimental evidence specific to IMRT dose delivery patterns is lacking. In this study we present cell survival data for three cell lines: Chinese hamster V79 fibroblasts, human cervical carcinoma, SiHa and colon adenocarcinoma, WiDr. Cell survival was obtained for 2.1 Gy delivered as acute dose with parallel-opposed pair (POP), irradiation time 75 s, which served as a reference; regular seven-field IMRT, irradiation time 5 min; and IMRT with a break for multiple leaf collimator (MLC) re-initialization after three fields were delivered, irradiation time 10 min. An actual seven-field dynamic MLC IMRT plan for a head and neck patient was used. The IMRT plan was generated for a Varian EX or iX linear accelerator with 120 leaf Millenium MLC. Survival data were also collected for doses 1X, 2X, 3X, 4X, and 5x 2.1 Gy to establish parameters of the linear-quadratic equation describing survival following acute dose delivery. Cells were irradiated inside an acrylic cylindrical phantom specifically designed for this study. Doses from both IMRT and POP were validated using ion chamber measurements. A reproducible increase in cell survival was observed following IMRT dose delivery. This increase varied from small for V79, with a surviving fraction of 0.8326 following POP vs 0.8420 following uninterrupted IMRT, to very pronounced for SiHa, with a surviving fraction of 0.3903 following POP vs 0.5330 for uninterrupted IMRT. When compared to IMRT or IMRT with a break for MLC initialization, cell survival following acute dose delivery was significantly different, p < 0.05, in three out of six cases. In contrast, when cell survival following IMRT was compared to that following IMRT with a break for MLC initialization the difference was always statistically insignificant. When projected to a 30 fraction treatment, dose deficit to bring cell survival to the same value as in POP was calculated as 4.1, 24.9, and 31.1 Gy for V79, WiDr, and SiHa cell lines, respectively. The dose deficit did not relate to the alpha/beta ratio obtained in this study for the three cell lines. Clinical data do not show reduction in local control following IMRT. Possible reasons for this are discussed. The obtained data set can serve as a test data set for models designed to explore the effect of dose delivery prolongation/fractionation in IMRT on radiation therapy outcome.

Entities:  

Mesh:

Year:  2007        PMID: 17500482     DOI: 10.1118/1.2712044

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  15 in total

1.  A study of the biological effects of modulated 6 MV radiation fields.

Authors:  Karl T Butterworth; Conor K McGarry; Joe M O'Sullivan; Alan R Hounsell; Kevin M Prise
Journal:  Phys Med Biol       Date:  2010-02-17       Impact factor: 3.609

2.  Out-of-field cell survival following exposure to intensity-modulated radiation fields.

Authors:  Karl T Butterworth; Conor K McGarry; Colman Trainor; Joe M O'Sullivan; Alan R Hounsell; Kevin M Prise
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

3.  Impact of decaying dose rate in gamma knife radiosurgery: in vitro study on 9L rat gliosarcoma cells.

Authors:  Ajay Niranjan; Glenn Gobbel; Josef Novotny; Jagdish Bhatnagar; Wendy Fellows; L Dade Lunsford
Journal:  J Radiosurg SBRT       Date:  2012

4.  Effect of prolonging radiation delivery time on retention of gammaH2AX.

Authors:  Vitali Moiseenko; Judit P Banáth; Cheryl Duzenli; Peggy L Olive
Journal:  Radiat Oncol       Date:  2008-06-27       Impact factor: 3.481

5.  A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT).

Authors:  Florian Stieler; Dirk Wolff; Frank Lohr; Volker Steil; Yasser Abo-Madyan; Friedlieb Lorenz; Frederik Wenz; Sabine Mai
Journal:  Radiat Oncol       Date:  2009-10-25       Impact factor: 3.481

6.  Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients.

Authors:  Filippo Alongi; Antonella Fogliata; Elena Clerici; Pierina Navarria; Angelo Tozzi; Tiziana Comito; Anna Maria Ascolese; Alessandro Clivio; Francesca Lobefalo; Giacomo Reggiori; Luca Cozzi; Pietro Mancosu; Stefano Tomatis; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2012-12-05       Impact factor: 3.481

7.  A retrospective planning analysis comparing intensity modulated radiation therapy (IMRT) to volumetric modulated arc therapy (VMAT) using two optimization algorithms for the treatment of early-stage prostate cancer.

Authors:  Craig A Elith; Shane E Dempsey; Helen M Warren-Forward
Journal:  J Med Radiat Sci       Date:  2013-09-02

8.  Implementation of Constant Dose Rate and Constant Angular Spacing Intensity-modulated Arc Therapy for Cervical Cancer by Using a Conventional Linear Accelerator.

Authors:  Ruo-Hui Zhang; Xiao-Mei Fan; Wen-Wen Bai; Yan-Kun Cao
Journal:  Chin Med J (Engl)       Date:  2016-02-05       Impact factor: 2.628

Review 9.  Clinical utility of RapidArc™ radiotherapy technology.

Authors:  Erminia Infusino
Journal:  Cancer Manag Res       Date:  2015-11-12       Impact factor: 3.989

Review 10.  Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?

Authors:  Yuta Shibamoto; Akifumi Miyakawa; Shinya Otsuka; Hiromitsu Iwata
Journal:  J Radiat Res       Date:  2016-03-22       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.